首页> 外文期刊>Oncology reports >Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy
【24h】

Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy

机译:使用新型双功能碘化连接物进行放射免疫治疗,提高放射性碘化抗表皮生长因子受体抗体的肿瘤保留

获取原文
获取原文并翻译 | 示例
           

摘要

Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target tumor cells. Radioiodine is most commonly employed to prepare radiolabeled proteins (antibodies, peptides) for in vitro and in vivo applications. A major shortcoming of radioiodinated proteins prepared by direct labeling methods is their deiodination in vivo. For the preparation of more stable radioiodinated antibodies, we developed a new linker (N-(4-isothiocyanatobenzyl)-2-(3-(tributylstannyl)phenyl) acetamide (IBPA). This study evaluated the usefulness of IBPA as a linker for the stable radioiodinated internalizing antibody, cetuximab. Directly labeled cetuximab ([I-125]-cetuximab) was prepared by the chloramine T method. To prepare indirectly labeled cetuximab using IBPA ([12(125)I]-IBPA-cetuximab), IBPA was radioiodinated using chloramine-T to give N-(4-isothiocyanatobenzyl)-2-(3-[I-125]phenyl)acetamide ([I-125]-IBPA), which was purified by high performance liquid chromatography. [I-125]-IBPA was then conjugated to cetuximab. In vitro target binding and internalizing assays were performed in PC9, LS174T, and FaDu cell lines. In vivo planar images were obtained using an Inveon SPECT scanner 3,24,48, and 168 h after i.v. injection of [I-125]-cetuximab or [I-125]-IBPA-cetuximab in athymic mice bearing LS174T tumor xenografts. Specific binding and internalized radioactivity of [I-125]-IBPA-cetuximab were higher than those of [I-125]-cetuximab in PC9, LS174T, and FaDu cell lines. In planar images scant radioactivity was evident in thyroid glands after injection of [I-125]-IBPA-cetuximab, while a high level of radioactivity was present in thyroid glands after injection of [I-125]-cetuximab. Tumor uptake value of [I-125]-IBPA-cetuximab was higher than that of [I-125]-cetuximab for up to 168 h. [I-125]-IBPA-cetuximab is stable and resistant to deiodination in vivo. IBPA is a promising bi-functional linker for radioiodination of internalizing monoclonal antibodies for in vivo applications including radioimmunotherapy.
机译:放射免疫疗法(RIT)使用标记有放射性核素的抗体将细胞毒性辐射传递至靶肿瘤细胞。放射性碘最常用于制备放射性标记的蛋白质(抗体,肽),以用于体外和体内应用。通过直接标记方法制备的放射性碘化蛋白的主要缺点是它们在体内的脱碘作用。为了制备更稳定的放射性碘标记的抗体,我们开发了一种新的接头(N-(4-异硫氰酸根合苄基)-2-(3-(三丁基锡烷基)苯基)乙酰胺(IBPA),该研究评估了IBPA作为该接头的有用性。稳定的放射性碘化内在化抗体西妥昔单抗,通过氯胺T法制备直接标记的西妥昔单抗([I-125]-西妥昔单抗),使用IBPA([12(125)I] -IBPA-cetuximab)间接制备西妥昔单抗,IBPA为用氯胺-T放射性碘化,得到N-(4-异硫氰酸根合苄基)-2-(3- [I-125]苯基)乙酰胺([I-125] -IBPA),将其通过高效液相色谱法纯化。然后将125] -IBPA结合到西妥昔单抗上,在PC9,LS174T和FaDu细胞系中进行体外靶结合和内在化实验,在3、24、48和168 h后使用Inveon SPECT扫描仪获得体内平面图像在携带LS174T肿瘤异种移植物的无胸腺小鼠中静脉注射[I-125]-西妥昔单抗或[I-125] -IBPA-西妥昔单抗。在PC9,LS174T和FaDu细胞系中,[I-125] -IBPA-西妥昔单抗的定性和内在放射性高于[I-125]-西妥昔单抗。在平面图像中,注射[I-125] -IBPA-西妥昔单抗后在甲状腺中放射活性很低,而注射[I-125]-西妥昔单抗后在甲状腺中存在高放射性。在长达168小时内,[I-125] -IBPA-西妥昔单抗的肿瘤吸收值高于[I-125]-西妥昔单抗的肿瘤吸收值。 [I-125] -IBPA-西妥昔单抗是稳定的,并且对体内的碘化作用具有抗性。 IBPA是一种有前途的双功能接头,可用于体内应用(包括放射免疫疗法)的内在化单克隆抗体的放射碘化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号